CVDs, recognized as chronic inflammatory conditions, are marked by notably heightened levels of inflammatory cytokines like IL-6, TNF-α, and IL-1β (38).Importantly, therapies targeting inflammation such as TNF-α and IL-6 inhibitors have shown promise in reducing CVDs incidence in RA (39). This evidence concerns the gene IL6 and rheumatoid arthritis.